Telix Pharmaceuticals (NASDAQ:TLX) Sees Strong Trading Volume After Analyst Upgrade

Telix Pharmaceuticals Limited (NASDAQ:TLX) saw unusually-high trading volume on Monday after Royal Bank Of Canada upgraded the stock from a hold rating to a moderate buy rating. 190,046 shares changed hands during mid-day trading, a decline of 9% from the previous session’s volume of 209,682 shares.The stock last traded at $11.49 and had previously closed at $12.59.

A number of other research analysts also recently issued reports on TLX. Weiss Ratings upgraded Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a report on Friday, August 21st. Wedbush reiterated an “outperform” rating and issued a $22.00 price objective on shares of Telix Pharmaceuticals in a research report on Monday, September 14th. Citigroup reissued a “buy” rating on shares of Telix Pharmaceuticals in a research note on Thursday, August 20th. Finally, HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of Telix Pharmaceuticals in a report on Tuesday, September 15th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $20.50.

Telix Pharmaceuticals News Roundup

Here are the key news stories impacting Telix Pharmaceuticals this week:

• Positive Sentiment: Telix agreed to acquire Germany’s ITM Isotope Technologies Munich in a transaction valued at up to $2.35 billion. The deal would combine Telix’s commercial radiopharmaceutical business with ITM’s radioisotope production and development capabilities, potentially creating a larger integrated oncology platform. Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse
• Positive Sentiment: The acquisition is intended to secure long-term access to critical medical isotopes, which could reduce supply-chain constraints and support Telix’s expanding cancer-diagnostics and therapeutic pipeline. Up to $700 million of the consideration is contingent on ITM’s lead drug receiving approval and achieving specified sales targets, limiting some upfront risk. Telix to Buy Germany’s ITM for Up to $2.35 Billion
• Positive Sentiment: Royal Bank of Canada upgraded Telix from “hold” to “moderate buy,” providing a supportive analyst signal after the acquisition-related selloff. Royal Bank of Canada Upgrade
• Neutral Sentiment: Management’s research and development presentation and merger call emphasized the strategic rationale and oncology pipeline, but investors will likely seek further details on integration, financing, regulatory approvals and the timing of expected synergies. Telix Research and Development Day Transcript
• Negative Sentiment: Telix’s shares fell sharply when the transaction was announced because the $1.65 billion upfront payment—largely in Telix shares—raises dilution concerns. The acquisition’s substantial size also increases integration, financing and execution risks, explaining the market’s initially negative reaction. Telix Stock Drops Following ITM Merger Deal

Hedge Funds Weigh In On Telix Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the stock. Hennion & Walsh Asset Management Inc. purchased a new position in shares of Telix Pharmaceuticals during the second quarter valued at about $1,731,000. Private Advisor Group LLC boosted its stake in shares of Telix Pharmaceuticals by 276.3% during the first quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock valued at $1,669,000 after purchasing an additional 128,070 shares during the period. XY Capital Ltd grew its stake in Telix Pharmaceuticals by 468.0% in the second quarter. XY Capital Ltd now owns 71,291 shares of the company’s stock worth $822,000 after purchasing an additional 58,739 shares in the last quarter. Lazard Asset Management LLC grew its holdings in Telix Pharmaceuticals by 15.7% during the 1st quarter. Lazard Asset Management LLC now owns 289,917 shares of the company’s stock worth $2,775,000 after acquiring an additional 39,400 shares in the last quarter. Finally, Bank of America Corp DE boosted its position in Telix Pharmaceuticals by 523.8% during the 1st quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock valued at $96,000 after acquiring an additional 8,423 shares in the last quarter.

Telix Pharmaceuticals Stock Up 5.7%

The company’s 50-day simple moving average is $11.32 and its 200 day simple moving average is $10.41. The company has a current ratio of 2.01, a quick ratio of 1.85 and a debt-to-equity ratio of 1.16.

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals for the diagnosis and treatment of cancer and other serious diseases. Its products use targeted molecules to deliver radioactive isotopes to specific tissues, supporting precision imaging and therapeutic applications.

The company’s commercial portfolio includes Illuccix, a gallium-68 radiolabeled prostate-specific membrane antigen (PSMA) imaging agent used with PET scans to help detect and manage prostate cancer.